Transcriptome sequencing identifies key pathways and genes involved in gastric adenocarcinoma

WENHU ZHANG, SHAOZHUANG LIU, HANXIANG ZHAN, ZHIBO YAN and GUANGYONG ZHANG

Department of General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China

Abstract. The present study aimed to investigate the key pathways and genes associated with gastric adenocarcinoma via transcriptome sequencing. Five pairs of gastric adenocarcinoma tissue and normal tumor-adjacent tissue were harvested. After sequencing, raw data were processed and differentially expressed genes (DEGs) between tumor and control groups were screened, followed by functional enrichment analysis and gene clustering analysis. The effect of DEGs on patient prognosis was analyzed on the basis of the survival data from gastric adenocarcinoma patients in The Cancer Genome Atlas database. Several genes were validated through reverse transcription-quantitative polymerase chain reaction. In total, 1,477 upregulated and 282 downregulated DEGs were screened in tumor groups. These genes were segregated into four clusters. Genes in cluster 1 were significantly involved in metabolism of xenobiotics by cytochrome P450, genes in cluster 2 were majorly involved in apoptosis, tight junction formation, and platelet activation, genes in cluster 3 were primarily enriched in the p53 signaling pathway and genes in cluster 4 were significantly enriched in the insulin resistance pathway. Furthermore, 15 DEGs significantly influenced prognosis, including *F2R*, *CTHRC1*, and *RASGRP3*. The expression levels of *CYP2B6*, *MAPK13*, *CTHRC*, *RASGRP3* and *PYGM* were consistent with our analysis results. In conclusion, pathways for metabolism of xenobiotics via cytochrome P450, apoptosis, tight junction formation, platelet activation, and insulin resistance may serve important roles in the progression of gastric adenocarcinoma. Notably, *CTHRC1* and *RASGRP3* may serve as key prognostic markers.

Introduction

Gastric cancer is the third leading cause of cancer-related mortality worldwide (1). Adenocarcinoma constitutes the majority, approximately 90%, of gastric cancer cases (2). Adenocarcinoma is a malignant epithelial tumor that invades the gastric wall, and infiltrates the muscularis mucosae, submucosa, and muscularis propria. Since early gastric cancer yields few symptoms, gastric cancer is usually advanced at diagnosis, which is difficult to cure (3). Advanced-stage gastric adenocarcinoma has a poor prognosis and the spontaneous median survival ranges from 3 to 6 months (4). Achieving a detailed understanding of the genetics and molecular pathogenesis of gastric adenocarcinoma may help improve patient outcomes.

Altered regulation of gene expression programs is important for tumors to express different cancer biomarkers (5,6). A Recent study has achieved considerable progress in identifying the key molecular mediators of gastric cancer. For instance, gene changes in Cadherin 1 expression, AT-rich interaction domain 1A, and ras homolog family member A, as well as some deregulated pathways including AMPK/HNF4a/Wnt5a pathways are associated with gastric malignancy and progression (7-10). Although several genes have been reported, a large proportion of gastric cancer patients have none of these genes in their cancer genome. Therefore, further detailed genomic characterization of gastric cancer patients is required.

Transcriptome sequencing is a rapidly developing approach to provide an unprecedented global view of the transcriptome, thereby revealing the entire transcriptional landscape (11,12). In this study, we used transcriptome sequencing to compare gene expression changes in five pairs of gastric adenocarcinoma tissue and normal tumor-adjacent tissue. Transcriptome sequencing data were then analyzed in silico. The present study aimed to further explore genetic and biochemical markers associated with gastric adenocarcinoma.

Materials and methods

Samples. Five pairs of gastric adenocarcinoma tissue and normal tumor-adjacent tissue were obtained from five gastric adenocarcinoma patients (Table I). The tissue samples were snap-frozen and stored in liquid nitrogen. All patients provided informed consent before the study. In addition, all procedures in this study were approved by our hospital's protection of human ethics committee.

RNA isolation, library preparation, and sequencing. Total RNAs were isolated from tumor and paired normal

Correspondence to: Dr Guangyong Zhang, Department of General Surgery, Qilu Hospital of Shandong University, 107 Wenhua Xi Road, Jinan, Shandong 250012, P.R. China
E-mail: guangyongzhang@hotmail.com

tumor-adjacent tissues using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). RNA integrity was detected using the RNA Nano 6000 Assay kit (Agilent Technologies, Inc., Santa Clara, CA, USA). RNA concentration and purity were assessed using Qubit®RNA Assay kit in Qubit®2.0 Flurometer (Thermo Fisher Scientific, Inc.), and NanoPhotometer® spectrophotometer (Implen, Inc., Westlake Village, CA), respectively. mRNA was then purified using oligo (dT) magnetic beads, and the high-quality mRNA were pooled to generate a cDNA library, using the NEBNext® Ultra™ RNA Library Prep kit for Illumina®. Briefly, mRNA was fragmented into small pieces, followed with first-strand cDNA synthesis with random hexamer-primers. Thereafter, double-stranded cDNA was synthesized and purified with AMPure XP beads. Purified double stranded cDNA was then subjected to end repair, dA tailing, and adaptor ligation. After size selection using AMPure XP beads, cDNA libraries were constructed and sequenced using the Illumina HiSeq 4000 platform.

The data are deposited at National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) database (accession no. SRP119102).

Raw read quality control and reference genome alignment. Raw reads were quality-filtered to obtain clear data via removal of adaptor sequences, ambiguous or low-quality reads and reads with more than 5% N, using Fastx toolkit version 0.0.13 and Prinseq-lite version 0.20.4 (13). The clear reads were aligned with the human reference genome GRCh38 using Tophat (version 2.0.8, http://htseq.readthedocs.io/) (14). The default parameters were the following: read-mismatches, 2; read-gap-length, 2; and min-anchor, 8. Thereafter, the clear reads were annotated using HTseq (version 0.6.1, http://www-huber.embl.de/HTSeq) (15) on the basis of the GRCh38 gene annotation information in gene code.

Identification of differentially expressed genes (DEGs) analysis. The mRNA read counts were transformed into log-counts per million (logCPM) using edger (version 3.4, http://www.bioconductor.org/packages/release/bioc/html/edgeR.html) in R (16,17). Genes with low expression values were excluded. The obtained genes were normalized using trimmed mean of M-values (TMM) algorithm. Thereafter, the normalized data were transformed into a gene expression matrix, using the voom method (18) in limma (version 3.32.5, http://bioconductor.org/packages/release/bioc/html/limma.html) package (19). DEGs were determined using empirical Bayes linear model and the P-value for the expression of all genes was obtained. A P-value <0.05 and $|\log_2$ (fold-change)$|\geq1$ were set as the cut-off values. The heatmap of DEGs was clustered using pheatmap (version 1.0.8, https://cran.r-project.org/web/packages/pheatmap) package in R (20).

Functional and pathway enrichment analyses. We used clusterProfiler (version 3.4.4, https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html) to implement Gene Ontology (GO) (21) and Kyoto Encyclopedia of Genes and Genomes (KEGG) (22) analyses for up- and down-regulated DEGs. The Benjamini and Hochberg (BH) method-adjusted P-value <0.05 was used as cut-off criteria.

Table I. Characteristics of patients.

Samples	Sex	Age	Height (cm)	Weight (kg)	Stage
G1	Male	64	170	55	T1N0M0
G2	Female	78	149	60	T2N2M1
G3	Male	63	172	65	T4aN2M0
G4	Female	84	155	55	T1N0M0
G5	Male	74	171	65	T1N0M0

Table II. Primers used in qPCR.

Primer name	Sequences (5'-3')
GAPDH-hF	TGACAACTTTGGTATCGTGGAAGG
GAPDH-hR	AGGCAGGGATGATGTTCTGGAGAG
CYP2B6-hF	TCCAGTCCATTACCGCCAAC
CYP2B6-hR	GTAAACTTGCCTGTGTGCCC
MAPK13-hF	CGTCAACAAGACAGCCTGGGA
MAPK13-hR	TGAAGACATCCAGGAGCCCAA
F2R-hF	CCGCCTGCTTCAGTCTGTG
F2R-hR	TGACCGGGGATCTAAGGTGG
CTHRC1-hF	CCGCCAGGTAGGAGCATCAC
CTHRC1-hR	TTTCCCTCAGACATTCCCCCT
RASGRP3-hF	TCAGTTTCTGACCTCCTGGCA
RASGRP3-hR	TGCATGGAAGAAGCAGTCTGT
PYGM-hF	AGAAGAGGCGGGAGAGGAAA
PYGM-hR	TGTTTGGGGGAGAAGAAGCC

Gene clustering analysis. On the basis of the gene expression valuesin cancer and control groups, we applied clustering analysis for DEGs using ConsensusClusterPlus (version 1.40.0, https://www.bioconductor.org/packages/release/bioc/html/ConsensusClusterPlus.html) in R (23). The clustering method was K-means algorithm with the Euclidean distance. The number of clusters was identified through cumulative distribution function (24).

PPI network and pathway analyses of clustering module. Based on the clustering modules obtained, we utilized the Search Tool for the Retrieval of Interacting Genes (STRING, Version 10.0, http://www.string-db.org/) (25) database to analyze protein-protein interactions among DEGs. The Cytoscape (version 3.4.0, http://www.cytoscape.org/) (26) software was used to visualize the PPI network. The topological characteristics of nodes in the network were analyzed using CytoNCA (version 2.1.6, http://apps.cytoscape.org/apps/cytonca) (27). Based on the topological propertyscores of nodes, hub proteins (28) were selected. Additionally, we performed KEGG pathway enrichment analysis for genes in clustering modules.

Prognostic analysis. The effect of DEGs on patient prognosis was analyzed using the stomach adenocarcinoma (STAD) survival data in The Cancer Genome Atlas (TCGA) database.

Figure 1. Heatmaps of differentially expressed genes between tumor and control samples. Red represents high expression; blue, low expression.

In TCGA database, we downloaded the mRNA-Seq and clinical data. In total, 371 samples displayed both gene expression values and clinical data, which were selected for prognostic analysis. Briefly, each DEG was divided into two groups in accordance with its expression level (relative to the median of expression value) in patients, followed by analysis using Kaplan-Meier (KM) survival curves. Significant differences between high- and low-expression groups were analyzed using the log-rank test.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) verification of the expression of key genes. The expression levels of several genes were detected using RT-qPCR based on the five pairs of gastric adenocarcinoma tissue and normal tumor-adjacent tissue. Briefly, total RNAs were isolated using a TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). RNA concentration and quality were determined on a TECAN infinite M100 PRO Biotek microplate reader (Tecan, San Jose, CA, USA). Then 0.5 μg of the total RNA was used from cDNA synthesis using the PrimeScript RT Master Mix (RR036A; Takara Biotechnology Co., Ltd., Dalian, China). RT-qPCR was performed using the SYBR-Green kit (4367659; Thermo Fisher Scientific, Inc.) in the Viia7 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The primers used in this study are listed in Table II.

Statistical analysis. Data are presented as mean ± standard deviation. Statistical analysis was performed using SPSS 22.0 (IBM Corp., Armonk, NY, USA). Differences in gene expression levels among different groups were analyzed by one-way analysis of variance. The least square difference test was used for post hoc analyses. P<0.05 was considered significant.

Results

Reference genome alignment. The reads mapped to the human reference genome (GRCh38). The alignment rates of ten samples ranged from 76.58% to 82.83% (data not shown).

Analysis of DEGs. In total, 1477 upregulated and 282 downregulated DEGs were screened out in tumor groups compared with the control. Clustering analysis revealed that DEGs could clearly distinguish between tumor and control groups, as shown in the heatmap (Fig. 1).

Functional enrichment analysis. Results of functional enrichment analysis are shown in Fig. 2. Upregulated DEGs were significantly associated with the binding of cell adhesion molecules, and cysteine-type endopeptidase activity, as well as the p53 signaling pathway, and TNF signaling pathway. Downregulated DEGs were significantly associated with the GO term 'ion channel binding', and pathway of 'Vascular smooth muscle contraction'.

Gene clustering analysis. Using the consensus cluster algorithm, when k=4, the consensus matrix plot (Fig. 3A) presented

Figure 2. Gene Ontology functions and Kyoto Encyclopedia of Genes and Genomes pathways enriched with upregualted and downregulated differentially expressed genes.


Figure 3. (A) Consensus matrix plots of differentially expressed genes; (B) Empirical cumulative distribution function (DF) plots; (C) Delta area plot.

a clear distribution of high consistency and low consistency in classification. Moreover, the classification achieved the maximum stability when k=4 (Fig. 3B). Furthermore, k=4 was the largest k with an appreciable increase in consensus (Fig. 3C). Therefore, k=4 was considered the optimal clustering number. Based on k=4, four clusters were obtained. The number of genes in clusters 1-4 was 410 (upregulated), 567 (479 upregulated and 88 downregulated), 591 (588 upregulated and 3 downregulated), and 191 (downregulated), respectively.

PPI network and pathway analyses of clustering module. The genes in the four clusters were subjected to PPI network analysis. The PPI network of cluster 1 comprised 192 nodes (such as non-SMC condensin I complex subunit H) and 511 edges

(Fig. 4); cluster 2, 440 nodes (such as mitogen-activated protein kinase 13 (*MAPK13*)) and 1,745 edges (Fig. 5); cluster 3, 385 nodes and 1,260 edges (Fig. 6); cluster 4, 40 nodes [glycogen phosphorylase, muscle associated (*PYGM*)] and 47 edges (Fig. 7). The top five genes with high degrees (hub genes) in the four networks are enlisted in Table III.

KEGG pathway enrichment analysis revealed that genes in cluster 1 were significantly involved in Maturity-onset diabetes among younger individuals, protein digestion and absorption, and xenobiotic metabolism via cytochrome P450; cluster 2, majorly involved in apoptosis, tight junction formation, and platelet activation; cluster 3, primarily enriched in the p53 signaling pathway, cell cycle, and TNF signaling pathway; cluster 4, significantly enriched in insulin resistance and neuroactive ligand-receptor interactions (Fig. 8).

Figure 4. The protein-protein interaction network generated on the basis of genes in the cluster 1. The gray round node represents upregualted genes.

Prognostic analysis. A total of 15 DEGs were identified to significantly influence patient prognosis (Table IV), including cystatin SA (*CST2*), coagulation factor II thrombin receptor (*F2R*), Collagen triple helix repeat containing 1 (*CTHRC1*), and RAS guanylreleasing protein 3 (*RASGRP3*). Furthermore, 9 genes were identified in cluster 3.

RT-qPCR verification of the expression of key genes. Expression levels of *CYP2B6*, *MAPK13*, *F2R*, *CTHRC*, *RASGRP3*, and *PYGM* were determined using RT-qPCR. As shown in Fig. 9, *CYP2B6*, *MAPK13*, and *CTHRC* were significantly upregulated in tumor samples compared with that in control samples (P<0.05). *RASGRP3* was also upregulated in tumor tissue but the difference was not significant. Additionally, *F2R* and *PYGM* were significantly downregulated in tumor samples compared with control (P<0.05). Taken together, the expression levels of *CYP2B6*, *MAPK13*, *CTHRC*, *RASGRP3* and *PYGM* were consistent with our analysis results.

Discussion

In total, 1,477 upregulated and 282 downregulated DEGs were screened out in tumor groups compared with the control. These genes were segregated into 4 clusters. Genes in cluster 1 were significantly involved metabolism of xenobiotics via cytochrome P450. Genes in cluster 2 were majorly involved in apoptosis, tight junction formation, and platelet activation. Genes in cluster 3 were primarily enriched in the p53 signaling pathway. Genes in cluster 4 were significantly enriched in the insulin resistance pathway. Furthermore, 15 DEGs were identified to significantly influence patient prognosis, including *F2R*, *CTHRC1*, and *RASGRP3*.

Cytochrome P450 enzymes are predominantly hepatic enzymes involved in drug and xenobiotic metabolism (29). However, reactive intermediates are formed during the conversion of the parent compound to the hydrophilic conjugated product that is cleared via excretion. These intermediates could

Figure 5. The protein-protein interaction network generated on the basis of genes in the cluster 2. The gray round node represents upregulated genes and white diamonds indicate downregulated genes.

cause genotoxicity and affect the checkpoint-signaling and stress-signaling pathways to cause aberrant cell growth and alter the cell cycle, thereby leading to tumor initiation (30). Interestingly, some cytochrome P450 family genes are correlated with the progression of gastric adenocarcinoma (31). The present study shows that three differentially expressed cytochrome P450 family genes (*CYP2B6*, *CYP2C9*, and *CYP3A4*) of cluster 1 were significantly enriched in xenobiotic metabolism via cytochrome P450 (hsa00980), suggesting that these DEGs may be involved in the development of gastric adenocarcinoma through xenobiotic metabolism via the cytochrome P450 pathway.

DEGs in cluster 2 were significantly enriched in apoptosis (hsa04210) and tight junction formation (hsa04530). These two pathways are associated with gastric tumorigenesis (32,33). Additionally, platelet activation (hsa04611) was also a significant

pathway among genes of cluster 2, which was enriched by *MAPK13* (a hub gene) and *F2R* (prognosis associated gene). *MAPK13* encodes the p38d isoform, which plays a role in the tumor initiation (34). Platelets are multifaceted cells, and circulating platelets can influence various pathophysiologic events (35). Platelets exacerbate tumor progression and metastasis (36,37). In 1968, Gasic *et al* (38) reported that thrombocytopenic mice are protected against metastasis, supporting the relevance of platelets in cancer progression. Together, pathways of apoptosis, tight junction formation, and platelet activation, as well as *MAPK13* and *F2R* may play important roles in gastric adenocarcinoma. Nevertheless, the *F2R* expression detected in RT-qPCR was inconsistent with the analysis results. Therefore, further study are needed to investigate the role of *F2R* in gastric adenocarcinoma. Prognostic analysis revealed that most of the

Figure 6. The protein-protein interaction network generated on the basis of genes in the cluster 3. The gray round node represents upregulated genes and white diamonds indicate downregulated genes.


Figure 7. The protein-protein interaction network generated on the basis of genes in the cluster 4. The white diamond node represents downregulated genes.

obtained prognosis-associated genes were present in cluster 3, including *CTHRC1* and *RASGRP3*. *CTHRC1* was first identified during screening of differentially expressed sequences between balloon-injured and normal rat arteries (39). It is overexpressed in several types of malignant tumors, including gastric cancer (40). Tang *et al* (41) reported that CTHRC1 plays key functional roles in cancer progression by increasing cancer cell invasion and metastasis. RASGRP3 is a member of the RASGRP family that was initially reported to be present in the screen of genes whose overexpression induce fibroblast transformation (42). The involvement of the RasGRP family in cancer progression and development is proving to be extensive (43,44). RASGRP3 could mediate the activation of the Ras signaling pathway, which plays a key role in carcinogenesis (45). Considering the critical roles of *CTHRC1* and *RASGRP3* in carcinogenesis and the present results, we considered the two genes as important prognostic markers in gastric adenocarcinoma.

PYGM, a hub gene in the PPI network of cluster 4, was involved in the insulin resistance pathway (hsa04931). Insulin resistance is a pathological condition characterized by a decline in the efficiency of insulin signaling for the regulation of blood sugar (46). Insulin is a potent mitogenic agent, which can inhibit apoptosis and promote cell proliferation (47).

Table III. Top five differentially expressed genes with high degrees (hub genes) in four networks.

Cluster	Node number	Up DEGs	Down DEGs	Edge number	Degree top 5 gene
Cluster 1	192	192	0	511	NCAPH, CDX1, DLGAP5, NCAPG, MNX1
Cluster 2	440	375	65	1,745	GGT1, MAPK13, ENO2, TRAP1, DUSP4
Cluster 3	385	384	1	1,260	AURKA, CDH17, MYBL2, CDC6, CFTR
Cluster 4	40	0	47	47	GHR, PYGM, CSF3, STX1B, FAM149A

Table IV. Differentially expressed genes that significantly affect patient prognosis.

Names	p	High.median	Low.median	Regulated	Cluster
CST2	0.042178	22.17	46.22	Up	1
CTSV	0.03481	25.59	57.39	Up	1
MATN3	0.000184	21.98	68.99	Up	1
SYT12	0.040832	25.59	46.22	Up	1
F2R	0.013663	25.59	55.39	Up	2
AADAC	0.047637	25.69	55.39	Up	3
AGT	0.025573	26.02	55.39	Up	3
TMEM243	0.031481	22.17	55.39	Up	3
CTHRC1	0.001409	23.39	59.49	Up	3
F5	0.001542	21.42	55.39	Up	3
KYNU	0.011683	25.03	59.49	Up	3
MSC	0.028155	25.16	46.22	Up	3
RASGRP3	0.035342	25.59	42.51	Up	3
SLC7A7	0.025332	22.17	42.51	Up	3
ADPRHL1	0.043589	42.51	26.08	Down	4

p, represents statistical significance analyzed via a log-rank test; High.median, represents median survival time in the high expression group; Low.median, represents median survival time in the low expression group; Regulated, represents variations in the expression level trends of genes (Tumor vs. Control).


Figure 8. Kyoto Encyclopedia of Genes and Genomes pathways enriched by genes in the four clusters.

Figure 9. Relative expression levels of *CTHRC1*, *CYP2B6*, *F2R*, *MAPK13*, *PYGM* and *RASGRP3* in gastric adenocarcinoma tissue and normal tumor-adjacent tissue determined by reverse transcription-quantitative polymerase chain reaction. Their expression levels are normalized against GAPDH. $^{*}P<0.05$, $^{**}P<0.01$.

Trevisan *et al* (48) reported that the variables related to an increase in insulin resistance are related to an increased risk of death from colorectal cancer. Furthermore, Mu *et al* (49) reported that insulin resistance was a risk factor for endometrial cancer. Therefore, we speculated that *PYGM* may be implicated in gastric adenocarcinoma via the insulin resistance pathway.

In conclusion, the present study suggested that pathways of xenobiotic metabolism via cytochrome P450, apoptosis, tight junction formation, platelet activation, and insulin resistance as well as the enriched genes including *CYP2B6*, *MAPK13*, and *PYGM* may play important roles in the progression of gastric adenocarcinoma. Furthermore, *CTHRC1* and *RASGRP3* may serve as key prognostic markers for gastric adenocarcinoma patients.

Acknowledgements

Funding

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

WHZ and SZL contributed to the study design, conducting the study, data analysis, and writing of the manuscript.

HXZ and ZBY contributed to the data collection and in conducting the study. GYZ contributed to data interpretation and discussion. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All procedures in this study were in accordance with the Declaration of Helsinki and approved by the protection of human ethics committee of Qilu Hospital of Shandong University.

Patient consent for publication

All patients provided informed consent for the study.

Competing interests

The authors declare that they have no competing interests.

References

1. Stewart B and Wild CP (eds): World Cancer Report 2014. IARC press, Lyon, 2015
2. Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64: 31-49, 1965.
3. Wadhwa R, Taketa T, Sudo K, Blum MA and Ajani JA: Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am 42: 359-369, 2013.
4. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006.
5. Chen X, Leung SY, Yuen ST, Chu KM, Ji J, Li R, Chan AS, Law S, Troyanskaya OG, Wong J, *et al*: Variation in gene expression patterns in human gastric cancers. Mol Biol Cell 14: 3208-3215, 2003.

6. Boussioutas A, Li H, Liu J, Waring P, Lade S, Holloway AJ, Taupin D, Gorringe K, Haviv I, Desmond PV and Bowtell DD: Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res 63: 2569-2577, 2003.

7. Tan P and Yeoh KG: Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology 149: 1153-1162.e3, 2015.

8. Pharoah PD, Guilford P and Caldas C; International Gastric Cancer Linkage Consortium: Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121: 1348-1353, 2001.

9. Chang HR, Nam S, Kook MC, Kim KT, Liu X, Yao H, Jung HR, Lemos R Jr, Seo HH, Park HS, *et al*: HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut: 19-32, 2014.

10. Kim YH, Liang H, Liu X, Lee JS, Cho JY, Cheong JH, Kim H, Li M, Downey TJ, Dyer MD, *et al*: AMPKα modulation in cancer progression: Multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res 72: 2512-2521, 2012.

11. Mäder U, Nicolas P, Richard H, Bessières P and Aymerich S: Comprehensive identification and quantification of microbial transcriptomes by genome-wide unbiased methods. Curr Opin Biotechnol 22: 32-41, 2011.

12. Zhang P, Li C, Zhu L, Su X, Li Y, Jin C and Li T: De novo assembly of the sea cucumber Apostichopus japonicus hemo-cytes transcriptome to identify miRNA targets associated with skin ulceration syndrome. PLoS One 8: 1254-1256, 2013.

13. Schmieder R and Edwards R: Quality control and preprocessing of metagenomic datasets. Bioinformatics 27: 863-864, 2011.

14. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R and Salzberg SL: TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14: R36, 2013.

15. Anders S, Pyl PT and Huber W: HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31: 166-169, 2015.

16. Robinson MD, McCarthy DJ and Smyth GK: edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26: 139-140, 2010.

17. McCarthy DJ, Chen Y and Smyth GK: Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res 40: 4288-4297, 2012.

18. Law CW, Chen Y, Shi W and Smyth GK: voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome biol 15: R29, 2014.

19. Smyth GK: Limma: Linear models for microarray data. In: Bioinformatics and computational biology solutions using R and Bioconductor. Springer, New York, NY, pp397-420, 2005.

20. Kolde R: pheatmap: Pretty heatmaps. R package version 1.0. 8. 2015.

21. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, *et al*: Gene ontology: Tool for the unification of biology. The gene ontology consortium. Nat Genet 25: 25-29, 2000.

22. Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Res 28: 27-30, 2000.

23. Wilkerson MD and Hayes DN: ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics 26: 1572-1573, 2010.

24. Xue B, Oldfield CJ, Dunker AK and Uversky VN: CDF it all: Consensus prediction of intrinsically disordered proteins based on various cumulative distribution functions. FEBS Lett 583: 1469-1474, 2009.

25. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, *et al*: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43: D447-D452, 2015.

26. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504, 2003.

27. Yu Tang ML, Jianxin, Wang Yi and Pan Fang-Xiang Wu: CytoNCA: A cytoscape plugin for centrality analysis and evaluation of biological networks. Biosystems 127: 67-72, 2015.

28. He X and Zhang J: Why do hubs tend to be essential in protein networks? PLoS Genet 2: e88, 2006.

29. Nebert DW and Dalton TP: The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6: 947, 2006.

30. Nebert DW and Russell DW: Clinical importance of the cyto-chromes P450. Lancet 360: 1155-1162, 2002.

31. Tsukino H, Kuroda Y, Qiu D, Nakao H, Imai H and Katoh T: Effects of cytochrome P450 (CYP) 2A6 gene deletion and CYP2E1 genotypes on gastric adenocarcinoma. Int J Cancer 100: 425-428, 2002.

32. Lee SK, Moon J, Park SW, Song SY, Chung JB and Kang JK: Loss of the tight junction protein claudin 4 correlates with histo-logical growth-pattern and differentiation in advanced gastric adenocarcinoma. Oncol Rep 13: 193-199, 2005.

33. Johnson AH, Frierson HF, Zaika A, Powell SM, Roche J, Crowe S, Moskaluk CA and El-Rifai W: Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. Am J Pathol 167: 577-584, 2005.

34. Yasuda K, Hirohashi Y, Kuroda T, Takaya A, Kubo T, Kanaseki T, Tsukahara T, Hasegawa T, Saito T, Sato N and Torigoe T: MAPK13 is preferentially expressed in gynecological cancer stem cells and has a role in the tumor-initiation. Biochem Biophys Res Commun 472: 643-647, 2016.

35. Franco AT, Corken A and Ware J: Platelets at the interface of thrombosis, inflammation and cancer. Blood 126: 582-588, 2015.

36. Nash GF, Turner LF, Scully MF and Kakkar AK: Platelets and cancer. Lancet Oncol 3: 425, 2002.

37. Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, *et al*: Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 89: 1098-1106, 2003.

38. Gasic GJ, Gasic TB and Stewart CC: Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 61: 46-52, 1968.

39. Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, Liaw L, Friesel RE and Lindner V: Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migra-tion. Circ Res 96: 261-268, 2005.

40. Wang P, Wang YC, Chen XY, Shen ZY, Cao H, Zhang YJ, Yu J, Zhu JD, Lu YY and Fang JY: CTHRC1 is upregulated by promoter demethylation and transforming growth factor-β1 and may be associated with metastasis in human gastric cancer. Cancer Sci 103: 1327-1333, 2012.

41. Tang L, Dai DL, Su M, Martinka M, Li G and Zhou Y: Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res 12: 3716-3722, 2006.

42. Ebinu JO, Bottorff DA, Chan EY, Stang SL, Dunn RJ and Stone JC: RasGRP, a Ras guanyl nucleotide-releasing protein with calcium-and diacylglycerol-binding motifs. Science 280: 1082-1086, 1998.

43. Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, *et al*: Response and resistance to MEK inhibition in leukaemias initiated by hyperac-tive Ras. Nature 461: 411-414, 2009.

44. Oki-Idouchi CE and Lorenzo PS: Transgenic overexpression of RasGRP1 in mouse epidermis results in spontaneous tumors of the skin. Cancer Res 67: 276-280, 2007.

45. Yang D, Kedei N, Li L, Tao J, Velasquez JF, Michalowski AM, Tóth BI, Marincsák R, Varga A, Bíró T, *et al*: RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype. Cancer Res 70: 7905-7917, 2010.

46. Djiogue S, Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y and Seke Etet PF: Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 20: R1-R17, 2013.

47. Bruce W and Corpet D: The colonic protein fermentation and insulin resistance hypotheses for colon cancer etiology: Experimental tests using precursor lesions. Eur J Cancer Prev 5: 41-47, 1996.

48. Trevisan M, Liu J, Muti P, Misciagna G and Menotti A; Risk Factors and Life Expectancy Research Group: Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 10: 937-941, 2001.

49. Mu N, Zhu Y, Wang Y, Zhang H and Xue F: Insulin resistance: A significant risk factor of endometrial cancer. Gynecol Oncol 125: 751-757, 2012.